Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
- P. Fenaux, G. Mufti, L. Silverman
- MedicineThe Lancet Oncology
- 1 March 2009
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
- P. Fenaux, G. Mufti, L. Silverman
- MedicineJournal of Clinical Oncology
- 1 February 2010
In older adult patients with low marrow blast count (20% to 30%) WHO-defined AML, azacitidine significantly prolongs OS and significantly improves several patient morbidity measures compared with CCR.
Guidelines for the diagnosis and management of adult aplastic anaemia
- S. Killick, N. Bown, J. Marsh
- MedicineBritish Journal of Haematology
- 1 January 2016
The authors thank Sally B. Killick, Nick Bown, Jamie Cavenagh, Inderjeet Dokal, Theodora Foukaneli, Peter Hillmen, Robin Ireland, Austin Kulasekararaj, Ghulam Mufti, John A Snowden, Sujith Samarasinghe and Anna Wood for their help.
TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.
- M. Jädersten, L. Saft, G. Mufti
- Medicine, BiologyJournal of Clinical Oncology
- 20 May 2011
It is demonstrated that TP53 mutated populations may occur at an early disease stage in almost a fifth of low-risk MDS patients with del(5q) and could indicate a previously unrecognized heterogeneity of the disease which may significantly affect clinical decision making.
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.
- L. Malcovati, E. Hellström-Lindberg, M. Cazzola
- MedicineBlood
- 24 October 2013
Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program and Guidelines were developed on the basis of a list of patient- and therapy-oriented questions.
CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment.
- P. Patten, A. Buggins, S. Devereux
- Biology, MedicineBlood
- 15 May 2008
It is shown that CD38 expression in CLL is dynamic, changes in response to contact with activated CD4(+) T cells, and identifies cells that are primed to proliferate, which suggests novel therapeutic targets.
Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes
- D. Bowen, D. Culligan, J. Parker
- Medicine, BiologyBritish Journal of Haematology
- 1 January 2003
The precise relationship between these pathological processes remains uncertain but has important implications for the design of new therapeutic strategies targeting either augmented apoptosis or acute myeloid leukaemia (AML).
Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres
- D. Kuter, B. Bain, G. Mufti, A. Bagg, R. Hasserjian
- Medicine, BiologyBritish Journal of Haematology
- 1 November 2007
A growing body of evidence suggests that increased deposition of bone marrow stromal fibres is mediated by transforming growth factor‐β and other factors elaborated by megakaryocytes, but it is likely that other cells, cytokines and growth factors are also involved.
Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells
- Abdelkader Essafi, S. F. D. Mattos, E. Lam
- Biology, ChemistryOncogene
- 31 March 2005
FoxO3a is confirmed as a key regulator of apoptosis induced by STI571, and it is shown that Bim is a direct transcriptional target of FoxO2a that mediates the STi571-induced apoptosis.
Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome.
- A. Kulasekararaj, Jie Jiang, G. Mufti
- Medicine, BiologyBlood
- 23 October 2014
It is postulated that somatic mutations are present in a subset of AA, and predict malignant transformation, and nearly one-fifth of AA patients harbor mutations in genes typically seen in myeloid malignancies that predicted for later transformation to MDS.
...
...